ES2049711T3 - Uso de bucilamina para la fabricacion de un medicamento para el tratamiento de cistinuria. - Google Patents

Uso de bucilamina para la fabricacion de un medicamento para el tratamiento de cistinuria.

Info

Publication number
ES2049711T3
ES2049711T3 ES93300048T ES93300048T ES2049711T3 ES 2049711 T3 ES2049711 T3 ES 2049711T3 ES 93300048 T ES93300048 T ES 93300048T ES 93300048 T ES93300048 T ES 93300048T ES 2049711 T3 ES2049711 T3 ES 2049711T3
Authority
ES
Spain
Prior art keywords
cystinuria
treatment
bucylamine
medicine
manufacture
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES93300048T
Other languages
English (en)
Other versions
ES2049711T1 (es
Inventor
Hisashi Baba
Hideo Takashina
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Santen Pharmaceutical Co Ltd
Original Assignee
Santen Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Santen Pharmaceutical Co Ltd filed Critical Santen Pharmaceutical Co Ltd
Publication of ES2049711T1 publication Critical patent/ES2049711T1/es
Application granted granted Critical
Publication of ES2049711T3 publication Critical patent/ES2049711T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

EL BACILAMINO O UNA SAL FARMACOLOGICAMENTE ACEPTABLE DEL MISMO, (POR EJEMPLO UNA SAL DE SODIO O DE POTASIO) SE USA PARA EL TRATAMIENTO Y/O PREVENCION DE LA CISTINURIA.
ES93300048T 1992-01-10 1993-01-06 Uso de bucilamina para la fabricacion de un medicamento para el tratamiento de cistinuria. Expired - Lifetime ES2049711T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP4040037A JP2814033B2 (ja) 1992-01-10 1992-01-10 シスチン尿症治療剤

Publications (2)

Publication Number Publication Date
ES2049711T1 ES2049711T1 (es) 1994-05-01
ES2049711T3 true ES2049711T3 (es) 1995-06-01

Family

ID=12569714

Family Applications (1)

Application Number Title Priority Date Filing Date
ES93300048T Expired - Lifetime ES2049711T3 (es) 1992-01-10 1993-01-06 Uso de bucilamina para la fabricacion de un medicamento para el tratamiento de cistinuria.

Country Status (5)

Country Link
US (1) US5266595A (es)
EP (1) EP0551180B1 (es)
JP (1) JP2814033B2 (es)
DE (2) DE69300037T2 (es)
ES (1) ES2049711T3 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5670545A (en) * 1996-02-09 1997-09-23 Board Of Regents Of The University Of Colorado Method for the treatment of ischemic disease and reperfusion injury and the prevention of the adverse effects of reactive oxygen species
CN1184965C (zh) 1999-06-21 2005-01-19 参天制药株式会社 骨关节炎的治疗剂
US20060275279A1 (en) * 2005-06-06 2006-12-07 Rozzell J D Methods for dissolving cystine stones and reducing cystine in urine
US9238018B2 (en) * 2012-11-20 2016-01-19 Revive Therapeutics Inc. Use of bucillamine in the treatment of gout
CA3071192A1 (en) * 2017-07-25 2019-01-31 Altibio, Inc. Modified-release bucillamine compositions, kits, and methods for treating cystinuria, arthritis, gout, and related disorders
MX2022001087A (es) * 2019-07-26 2022-04-07 Fundacio Inst Dinvestigacio Biomedica De Bellvitge Idibell Ergotioneina, s-metil-ergotioneina, y usos de las mismas.

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS535112A (en) * 1976-03-08 1978-01-18 Santen Pharmaceutical Co Ltd New cysteine derivatives

Also Published As

Publication number Publication date
EP0551180A1 (en) 1993-07-14
DE69300037D1 (de) 1995-02-09
EP0551180B1 (en) 1994-12-28
DE69300037T2 (de) 1995-06-29
US5266595A (en) 1993-11-30
JPH05186341A (ja) 1993-07-27
ES2049711T1 (es) 1994-05-01
JP2814033B2 (ja) 1998-10-22
DE551180T1 (de) 1994-02-03

Similar Documents

Publication Publication Date Title
MX9203444A (es) Medicamentos.
ES2186787T3 (es) Utilizacion de ritonavir (abt-538) para mejorar la farmacocinetica de medicamentos metabolizados por el citocromo p450 en un metodo de tratamiento del sida.
MX9204268A (es) Una composicion para la liberacion prolongada y controlada de substancias medicamentosas y un proceso para preparar la misma.
ES2083668T3 (es) Combinaciones antiviricas que contienen analogos de nucleosidos.
MX9300662A (es) Derivados fosfonooxi y carbonato de taxol
EA200100541A1 (ru) Фармацевтическая композиция с модифицированным высвобождением сенсибилизатора к инсулину и других антидиабетических агентов
PT83872A (de) Arzneimittel
AR015940A1 (es) Derivados de rapamicina que contiene tetrazol con vidas medias acortadas y su uso para la manufactura de un medicamento
ES2157252T3 (es) Aplicacion del riluzol en el tratamiento del neuro-sida.
MX9305248A (es) Compuestos de diarilpiperazinoacetamida.
MX9706957A (es) Composicion que contiene amlodipina, o una sal, o felodipina y un inhibidor de enzima convertidora de angiotensina.
ES2063186T3 (es) Derivados ftalinida, composicion farmaceutica y uso.
ES2171459T3 (es) Polvo para administracion nasal de farmaco peptidico o proteinaceo.
ES2049711T3 (es) Uso de bucilamina para la fabricacion de un medicamento para el tratamiento de cistinuria.
ES2177024T3 (es) Empleo de la fanquinoma para el tratamiento de la enfermedaad de alzheimer.
ES2187534T3 (es) Procedimiento para la preparacion de n-metil-3-(metil-4-piperi dinil)-14-indol-5-etanosulfonamida.
ES2101747T3 (es) Penciclovir y famciclovir y derivados de guanina relacionados para el tratamiento de infecciones por vih-1.
ES2072386T3 (es) Derivados del penciclovir para el tratamiento de las infecciones de hepatitis-b.
ES2191908T3 (es) 4-aminopirrol(3,2-d)pirimidinas como antagonistas del receptor del neuropeptido.
BG102404A (en) The application of flupirtin for the prevention and treatment of diseases related to impairement of the haematopoeic cellular system
FR2632525B1 (fr) Application therapeutique de la myeloperoxydase humaine
TW330933B (en) Furanoeremophilane and eremophilanolide sesquiterpenes for treatment of diabetes
ES2058349T3 (es) Utilizacion de betabloqueadores para el tratamiento de la progresion de la miopia axial infantil.
ES2070148T3 (es) Derivado de la glicerina y utilizacion farmacologica del mismo.
ATE57526T1 (de) P-acylaminobenzamide.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 551180

Country of ref document: ES